2-(2-furyl)ethenyl isocyanate | 76197-67-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 2-(2-furyl)ethenyl isocyanate
• 英文别名: 2-[(E)-2-isocyanatoethenyl]furan
• CAS: 76197-67-6
• 化学式: C₇H₅NO₂
• 分子量: 135.122
• InChiKey: GYJKEOYTXSMUAU-ONEGZZNKSA-N

物化性质

• 沸点：
  193.9±32.0 °C(predicted)
• 密度：
  1.08±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-氟脲嘧啶 、 2-(2-furyl)ethenyl isocyanate 以 N,N-二甲基乙酰胺 为溶剂， 生成 1-[N-[2-(trans-2-furyl)ethenyl]carbamoyl]-5-fluorouracil
  参考文献：
  名称：

  5-Fluorouracil derivatives, and their pharmaceutical compositions

  摘要：

  一种化合物的化学式为：##STR1##其中R是从诺伯尼尔、诺伯烯基、双环[2,2,2]-庚基和金刚烷基中选择的桥环脂环基，可选择地被来自较低烷基、羧基、较低烷氧羰基、烷基二氧基、N,N-双(较低)烷基氨基甲酰、氨基、较低烷氧羰胺基和卤素的至少一种取代基取代。该化合物可用于治疗人类和动物的癌症。

  公开号：

  US04349552A1
• 作为产物：
  描述：

  呋喃-2-丙烯酸叠氮化物 以 苯 为溶剂， 反应 24.0h， 生成 2-(2-furyl)ethenyl isocyanate
  参考文献：
  名称：

  NEW COMPOUND FOR INHIBITING BINDING BETWEEN DX2 PROTEIN AND P14/ARF PROTEIN, AND PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER DISEASE CONTAINING SAME AS EFFECTIVE INGREDIENT

  摘要：

  披露了一种新化合物，该化合物抑制了DX2蛋白与p14/ARF蛋白之间的结合，包括该新化合物作为治疗或预防癌症疾病的有效成分的药物组合物，用于提高耐药抗癌药物的抗癌效果的抗癌辅助剂，以及包括AIMP2-DX2蛋白或其片段的组合物，用于诊断肺癌。

  公开号：

  US20170129904A1

文献信息

• 5-Fluorouracil derivatives, preparation thereof and their pharmaceutical compositions
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0010941A1

  公开（公告）日：1980-05-14

  The present invention provides compounds of the general formula:- wherein R is an optionally substituted bridged alicyclic radical or a substituted lower alkyl radical, the substituent being an optionally substituted bridged alicyclic group, an amino, protected amino, lower alkoxy, acyl, lower alkylthio, cyano(lower)alkylthio, arylthio or optionally substituted heterocyclic radical or a carboxy and esterified carboxy group, with the proviso, that when the substituent is a carboxy or esterified carboxy group then the lower alkyl radical contains 3 to 6 carbon atoms; or an unsubstituted or substituted lower alkenyl radical, the substituent being an optionally substituted bridged alicyclic group, an optionally substituted aryl radical or an optionally substituted heterocyclic radical; or a halophenyl radical; or an optionally substituted heterocyclic radical. 'The present invention also provides processes for the preparation of these compounds and pharmaceutical composition containing them. Furthermore, the present invention is concerned with a method of treating cancer which comprises administering these compounds to mammals suffering from cancer.

  本发明提供通式为：- 的化合物。 其中 R 是任选取代的桥式脂环基或取代的低级烷基，取代基是任选取代的桥式脂环基、氨基、保护氨基、低级烷氧基、酰基、低级烷硫基、氰基（低级）烷硫基、芳硫基或任选取代的杂环基或羧基和酯化羧基，但条件是当取代基是羧基或酯化羧基时，低级烷基含有 3 至 6 个碳原子；或未取代或取代的低级烯基，取代基为任选取代的桥式脂环基、任选取代的芳基或任选取代的杂环基；或卤代苯基；或任选取代的杂环基。 '本发明还提供了制备这些化合物和含有这些化合物的药物组合物的工艺。此外，本发明还涉及一种治疗癌症的方法，该方法包括对患有癌症的哺乳动物施用这些化合物。
• Compound for inhibiting binding between DX2 protein and p14/ARF protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient
  申请人：PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION

  公开号：US10280178B2

  公开（公告）日：2019-05-07

  Disclosed is a new compound that inhibits binding between a DX2 protein and a p14/ARF protein, a pharmaceutical composition including the new compound as an effective component for treating or preventing a cancer disease, an anticancer adjuvant for improving an anticancer effect of a drug-resistant anticancer drug, and a composition including an AIMP2-DX2 protein or a fragment thereof for diagnosing lung cancer.

  公开了一种抑制 DX2 蛋白和 p14/ARF 蛋白之间结合的新化合物、一种包括新化合物作为有效成分用于治疗或预防癌症疾病的药物组合物、一种用于改善耐药抗癌药物抗癌效果的抗癌辅助剂，以及一种包括 AIMP2-DX2 蛋白或其片段用于诊断肺癌的组合物。
• Synthesis and evaluation of ureido and vinylureidopenicillins as inhibitors of intraruminal lactic acid production
  作者：Robin D. Clark、Joan M. Caroon、Ian T. Harrison、Arthur F. Kluge、Stefan H. Unger、Howard R. Spires、Thomas R. Mathews

  DOI：10.1021/jm00142a024

  日期：1981.10

  A series of 14 vinylureidopenicillins and a series of 9 ureidopenicillins were prepared by reaction of 6-aminopenicillanic acid with vinyl isocyanates and isocyanates. These compounds were evaluated for their potential to protect ruminants against lactic acidosis. The compounds were tested for inhibition of in vitro ruminal lactic and propionic acid production, and six compounds inhibited lactic acid production to less than 10% of control at doses of 0.31 microgram/mL or lower, whereas they did not inhibit propionic acid production at doses greater than 10 micrograms/mL. The most active compounds also were screened for general antibacterial activity and were found to be weakly active against Gram-positive bacteria. The structure--activity relationships are discussed for both series. Triethylammonium 6-[3[2-(4-tert-butylphenyl)vinyl]ureido]penicillanate (4) was chosen for evaluation as an inhibitor of intraruminal lactic acidosis in vivo.
• US4349552A
  申请人：——

  公开号：US4349552A

  公开（公告）日：1982-09-14
• NEW COMPOUND FOR INHIBITING BINDING BETWEEN DX2 PROTEIN AND P14/ARF PROTEIN, AND PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER DISEASE CONTAINING SAME AS EFFECTIVE INGREDIENT
  申请人：PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION

  公开号：US20170129904A1

  公开（公告）日：2017-05-11

  Disclosed is a new compound that inhibits binding between a DX2 protein and a p14/ARF protein, a pharmaceutical composition including the new compound as an effective component for treating or preventing a cancer disease, an anticancer adjuvant for improving an anticancer effect of a drug-resistant anticancer drug, and a composition including an AIMP2-DX2 protein or a fragment thereof for diagnosing lung cancer.

  披露了一种新化合物，该化合物抑制了DX2蛋白与p14/ARF蛋白之间的结合，包括该新化合物作为治疗或预防癌症疾病的有效成分的药物组合物，用于提高耐药抗癌药物的抗癌效果的抗癌辅助剂，以及包括AIMP2-DX2蛋白或其片段的组合物，用于诊断肺癌。